|
![]() |
|
|
Galantamine
drug data and news
Galantamine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Galantamine | ||
| Brand Names/Synonyms | Galantamin; Galantamine; Galanthamine; Galanthamine Base; Galanthamine Hydrobromide; Jilkon; Lycoremin; Lycoremine; Reminyl | ||
| Indication | For the treatment of mild to moderate dementia of the Alzheimer's type. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process. | ||
| Mechanism Of Action | Galantamine's proposed mechanism of action involves the increase of the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. | ||
| Galantamine News (When available) |
Healthy lifestyle lowers risk of dementia caused by white matter ... 07 Mar 2006 Shire plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006 Alzheimer’s Disease Questions and Answers Feb 28, 2006 Evotec completes Phase I component for Alzheimer’s drug Feb 8, 2006 Health Tip: There's No Cure for Alzheimer's Feb 9, 2006 Improving Alzheimer’s treatment Feb 6, 2006 Bilateral chronic subdural haematoma: a reversible cause of ... Feb 9, 2006 Drug Side Effects Can Befuddle Elderly Feb 1, 2006 Health Tip: There's No Cure for Alzheimer's 09 Feb 2006 Evotec completes Phase I component for Alzheimer’s drug Feb 8, 2006 Improving Alzheimer’s treatment Feb 6, 2006 NICE Consults On Revised First Draft Guidance On The Use Of Drugs ... Jan 24, 2006 Alzheimer's drugs to be available to NHS patients Jan 22, 2006 Drug Side Effects Can Befuddle Elderly Feb 1, 2006 Alzheimer's and the need for swift treatment Jan 30, 2006 Veggie-burger blues: Soy slips as cholesterol reducer Jan 27, 2006 NICE (National Institute for Health and Clinical Excellence) ... Jan 22, 2006 Alzheimer's Drugs Aricept, Razadyne And Exelon Offer Modest ... Jan 25, 2006 Guidance rules out early treatment for Alzheimer's Jan 22, 2006 Thousands of Scots Alzheimer's sufferers will be denied drugs Jan 22, 2006 Alzheimer sufferers win £60m drug fight Jan 21, 2006 Alzheimer's drugs policy reviewed Jan 22, 2006 UK - New guidance on Alzheimer's drugs Jan 23, 2006 RCP: Nice guidance is still flawed Jan 23, 2006 Nice reverses Alzheimer's drug decision Jan 23, 2006 Anger over Alzheimer's drugs ruling Jan 23, 2006 Alzheimer's Society: Nice decision is mixed Jan 23, 2006 Nice: Alzheimer's patients will benefit from decision Jan 23, 2006 Today's issue...Alzheimer's drugs Jan 23, 2006 DEMENTIA sufferers have been given fresh hope after a U-turn by ... Jan 23, 2006 NICE (National Institute for Health and Clinical Excellence) ... Jan 22, 2006 Apathy and Its Treatment in Alzheimer's Disease and Other ... Dec 5, 2005 Medications Used to Treat ADHD Nov 30, 2005 Cortical Activation During Cholinesterase-Inhibitor Treatment in ... Nov 13, 2005 Confusion, losing place could be signs of dementia Nov 20, 2005 Cholinesterase inhibitors: in search of cholinergic deficits Sep 16, 2005 Stem Cell Research Essential Oct 3, 2005 Alzheimer's sufferers hit by further delay in NHS approval for ... Sep 17, 2005 Understanding dementia Sep 23, 2005 EU funded project develops intelligent device for controlled drug ... Sep 24, 2005 COMPANY OF THE YEAR: Johnson & Johnson Sep 15, 2005 | ||
| Dosage Forms | CAPSULE, EXTENDED RELEASE | ||
| Drug_Category | Nootropic Agents; Parasympathomimetics; Parasympathomimetics; ATC:N06DA04 | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | LD50=75 mg/kg (rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol | ||
| Chemical Formula | C17H21NO3 | ||
| Molecular Weight | 287.354 g/mol | ||
| Smiles String | CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O | ||
| Melting Point | 269-270 oC (HBr salt) | ||
| Water Solubility | 10 mg/mL (HBr salt) | ||
| State | Solid | ||
| LogP/Hphobicity | 2.369 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 7 hours | ||
| Protein Binding [%] | 18% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Galantamine.html http://www.rxlist.com/cgi/generic/reminyl.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00206 | ||
| CAS Registry Number | 357-70-0 | ||
| KEGG Compound ID | C08526 | ||
| PubChem ID | SID:10719 | ||
| PharmGKB ID | PA449726 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2266717 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |